Form 4: CytomX Therapeutics Director Elaine V. Jones Reports Stock Option Grant

Director Elaine V. Jones reports the acquisition of stock options in CytomX Therapeutics.

Summary

• Elaine V. Jones, a director of CytomX Therapeutics, Inc. (CTMX), filed a Form 4 on May 17, 2024, reporting a transaction.
• On May 15, 2024, Jones acquired 38,000 stock options with an exercise price of $1.96.
• The options vest on the earlier of the first anniversary of the grant date or the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
• Following the transaction, Jones directly owns 38,000 derivative securities (stock options).

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to stock option grants, and does not contain any information that would significantly impact investor sentiment positively or negatively.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service as a director.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option grants are a common form of compensation for directors and executives in the biotechnology industry, aligning their interests with the long-term success of the company.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised in the future.
• The grant incentivizes the director to act in the best interests of the company and its shareholders.

Key Dates